These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 24165902)

  • 1. Poly(lactic acid) nanoparticles of the lead anticancer ruthenium compound KP1019 and its surfactant-mediated activation.
    Fischer B; Heffeter P; Kryeziu K; Gille L; Meier SM; Berger W; Kowol CR; Keppler BK
    Dalton Trans; 2014 Jan; 43(3):1096-104. PubMed ID: 24165902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019.
    Bartel C; Egger AE; Jakupec MA; Heffeter P; Galanski MS; Berger W; Keppler BK
    J Biol Inorg Chem; 2011 Dec; 16(8):1205-15. PubMed ID: 21706338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies of KP46 and KP1019 and the Hydrolysis Product of KP1019 in Lipiodol Emulsions: Preparation and Initial Characterizations as Potential Theragnostic Agents.
    Pashkunova-Martic I; Losantos BC; Kandler N; Keppler B
    Curr Drug Deliv; 2018; 15(1):134-142. PubMed ID: 28000552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.
    Heffeter P; Böck K; Atil B; Reza Hoda MA; Körner W; Bartel C; Jungwirth U; Keppler BK; Micksche M; Berger W; Koellensperger G
    J Biol Inorg Chem; 2010 Jun; 15(5):737-48. PubMed ID: 20221888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.
    Webb MI; Wu B; Jang T; Chard RA; Wong EW; Wong MQ; Yapp DT; Walsby CJ
    Chemistry; 2013 Dec; 19(50):17031-42. PubMed ID: 24203647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoformulation improves activity of the (pre)clinical anticancer ruthenium complex KP1019.
    Heffeter P; Riabtseva A; Senkiv Y; Kowol CR; Körner W; Jungwith U; Mitina N; Keppler BK; Konstantinova T; Yanchuk I; Stoika R; Zaichenko A; Berger W
    J Biomed Nanotechnol; 2014 May; 10(5):877-84. PubMed ID: 24734541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of KP1019 and NAMI-A in tumour-mimetic environments.
    Gransbury GK; Kappen P; Glover CJ; Hughes JN; Levina A; Lay PA; Musgrave IF; Harris HH
    Metallomics; 2016 Aug; 8(8):762-73. PubMed ID: 27460862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CF3 Derivatives of the Anticancer Ru(III) Complexes KP1019, NKP-1339, and Their Imidazole and Pyridine Analogues Show Enhanced Lipophilicity, Albumin Interactions, and Cytotoxicity.
    Chang SW; Lewis AR; Prosser KE; Thompson JR; Gladkikh M; Bally MB; Warren JJ; Walsby CJ
    Inorg Chem; 2016 May; 55(10):4850-63. PubMed ID: 27143338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruthenium anticancer agent KP1019 binds more tightly than NAMI-A to tRNA
    Dwyer BG; Johnson E; Cazares E; McFarlane Holman KL; Kirk SR
    J Inorg Biochem; 2018 May; 182():177-183. PubMed ID: 29501978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chitosan/PLA nanoparticles as a novel carrier for the delivery of anthraquinone: synthesis, characterization and in vitro cytotoxicity evaluation.
    Jeevitha D; Amarnath K
    Colloids Surf B Biointerfaces; 2013 Jan; 101():126-34. PubMed ID: 22796782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Deceptively Similar Ruthenium(III) Drug Candidates KP1019 and NAMI-A Have Different Actions. What Did We Learn in the Past 30 Years?
    Alessio E; Messori L
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osmium(III) analogues of KP1019: electrochemical and chemical synthesis, spectroscopic characterization, X-ray crystallography, hydrolytic stability, and antiproliferative activity.
    Kuhn PS; Büchel GE; Jovanović KK; Filipović L; Radulović S; Rapta P; Arion VB
    Inorg Chem; 2014 Oct; 53(20):11130-9. PubMed ID: 25290960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced anti-topoisomerase II activity by mucoadhesive 4-CBS-chitosan/poly (lactic acid) nanoparticles.
    Songsurang K; Suvannasara P; Phurat C; Puthong S; Siraleartmukul K; Muangsin N
    Carbohydr Polym; 2013 Nov; 98(2):1335-42. PubMed ID: 24053811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-cancer evaluation of quercetin embedded PLA nanoparticles synthesized by emulsified nanoprecipitation.
    Pandey SK; Patel DK; Thakur R; Mishra DP; Maiti P; Haldar C
    Int J Biol Macromol; 2015 Apr; 75():521-9. PubMed ID: 25701491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanism of poly(vinyl alcohol) mediated prevention of aggregation and stabilization of insulin in nanoparticles.
    Rawat S; Gupta P; Kumar A; Garg P; Suri CR; Sahoo DK
    Mol Pharm; 2015 Apr; 12(4):1018-30. PubMed ID: 25644480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.
    Polec-Pawlak K; Abramski JK; Semenova O; Hartinger CG; Timerbaev AR; Keppler BK; Jarosz M
    Electrophoresis; 2006 Mar; 27(5-6):1128-35. PubMed ID: 16440400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer ruthenium(III) complex KP1019 interferes with ATP-dependent Ca2+ translocation by sarco-endoplasmic reticulum Ca2+-ATPase (SERCA).
    Sadafi FZ; Massai L; Bartolommei G; Moncelli MR; Messori L; Tadini-Buoninsegni F
    ChemMedChem; 2014 Aug; 9(8):1660-4. PubMed ID: 24920093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anticancer ruthenium complex KP1019 induces DNA damage, leading to cell cycle delay and cell death in Saccharomyces cerevisiae.
    Stevens SK; Strehle AP; Miller RL; Gammons SH; Hoffman KJ; McCarty JT; Miller ME; Stultz LK; Hanson PK
    Mol Pharmacol; 2013 Jan; 83(1):225-34. PubMed ID: 23090979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin.
    Groessl M; Zava O; Dyson PJ
    Metallomics; 2011 Jun; 3(6):591-9. PubMed ID: 21399784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of surfactant surface coverage on formation of solid lipid nanoparticles (SLN).
    Helgason T; Awad TS; Kristbergsson K; McClements DJ; Weiss J
    J Colloid Interface Sci; 2009 Jun; 334(1):75-81. PubMed ID: 19380149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.